Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults

Media type: E-Article
Title: Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults
Contributor: He, Lingxiao; de Souto Barreto, Philipe; Aggarwal, Geetika; Nguyen, Andrew D.; Morley, John E.; Li, Yan; Bateman, Randall J.; Vellas, Bruno; Vellas, Bruno; Guyonnet, Sophie; Carrié, Isabelle; Brigitte, Lauréane; Faisant, Catherine; Lala, Françoise; Delrieu, Julien; Villars, Hélène; Combrouze, Emeline; Badufle, Carole; Zueras, Audrey; Andrieu, Sandrine; Cantet, Christelle; Morin, Christophe; Van Kan, Gabor Abellan; Dupuy, Charlotte; [...]
imprint: Springer Science and Business Media LLC, 2020
Published in: Alzheimer's Research & Therapy
Language: English
DOI: 10.1186/s13195-020-00697-0
ISSN: 1758-9193
Origination:
Footnote:
Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Cognition is closely associated with physical function. Although high brain amyloid-β (Aβ) deposition and neurofilament light chain (NfL) are associated with cognitive and gait speed decline, relationships of combined plasma Aβ and NfL profiles with cognitive and physical functions in older adults remain unknown. The research aim of this study was to investigate the prospective associations of combined plasma Aβ and NfL profiles with cognitive and physical functions in older adults.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Participants (<jats:italic>n</jats:italic> = 452, aged 76 ± 5 years) who had both plasma Aβ and NfL data collected from the Multidomain Alzheimer’s Preventive Trial (MAPT, May 2008 to April 2016) were included in the current study. These participants were from four MAPT groups (multidomain interventions [physical activity and nutritional counselling, and cognitive training], omega-3 supplementation, multidomain plus omega-3 supplementation and control group) and had received a 3-year intervention, followed by a 2-year observational follow-up. Cognitive function was evaluated as Mini-Mental State Examination and composite cognitive score (CCS, a mean<jats:italic>Z</jats:italic>-score combining four cognitive tests). Physical function was evaluated as gait speed (4-m usual-pace walk test) and chair-stand time (5-time maximal chair-stand test). Cognitive and physical function data measured at the time of and after blood Aβ and NfL tests were used for analysis. Participants with plasma Aβ<jats:sub>42</jats:sub>/Aβ<jats:sub>40</jats:sub>ratios lower than 0.107 and NfL levels greater than 93.04 pg/ml were classified as Aβ+ and NfL+. Multivariable regressions and mixed-effects linear models were used for the analysis.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>At the cross-sectional level, no significant association was found between Aβ+NfL+ and cognitive or physical function after controlling for age, sex, body mass index, education level and MAPT group. Evaluating longitudinal changes, participants with Aβ+NfL+ had greater annual declines in the CCS (<jats:italic>β</jats:italic> = − 0.11, 95%CI [− 0.17, − 0.05]) and gait speed (<jats:italic>β</jats:italic> = − 0.03, 95%CI [− 0.05, − 0.005]). After adjusting for APOE ɛ4 genotype, Aβ+NfL+ was associated with a greater decline only in the CCS (<jats:italic>β</jats:italic> = − 0.09, 95%CI [− 0.15, − 0.02]).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Combined low plasma Aβ<jats:sub>42</jats:sub>/Aβ<jats:sub>40</jats:sub>ratio and high plasma NfL level was associated with greater declines in cognition and gait speed over time, providing further evidence of the links between cognitive and physical function.</jats:p></jats:sec><jats:sec><jats:title>Trial registration</jats:title><jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</jats:ext-link>[<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT00672685?term=NCT00672685&cntry=FR&draw=2&rank=1">NCT00672685</jats:ext-link>].</jats:p></jats:sec>
Access State: Open Access

Search in field:

Recently searched for: